---
title: "Oppenheimer Keeps Their Buy Rating on Protara Therapeutics (TARA)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286430766.md"
description: "Oppenheimer analyst reiterated a Buy rating on Protara Therapeutics today and set a price target of $25.00.Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Currently, the analyst consensus on Protara Therapeutics is a Strong Buy with an average price target of $25.83."
datetime: "2026-05-14T14:06:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286430766.md)
  - [en](https://longbridge.com/en/news/286430766.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286430766.md)
generator: "portal-rs"
---

# Oppenheimer Keeps Their Buy Rating on Protara Therapeutics (TARA)

Oppenheimer analyst reiterated a Buy rating on Protara Therapeutics today and set a price target of $25.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Currently, the analyst consensus on Protara Therapeutics is a Strong Buy with an average price target of $25.83.

### Related Stocks

- [TARA.US](https://longbridge.com/en/quote/TARA.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [OPY.US](https://longbridge.com/en/quote/OPY.US.md)

## Related News & Research

- [FDA grants priority review to Genentech’s Enspryng for MOGAD](https://longbridge.com/en/news/298539804.md)
- [09:28 ETNew LabCentral Program "The Loop" Offers International Biotech Start-Ups and Partner Organizations Curated Learnings Directly from U.S. Market](https://longbridge.com/en/news/298328140.md)
- [Protara Therapeutics: Strategic Trial Shift and Strong Cash Runway Support Buy Rating Despite Price Target Cut to $20 From $26](https://longbridge.com/en/news/295589045.md)
- [Protara Therapeutics Q2 net loss widens on higher expenses](https://longbridge.com/en/news/295534784.md)
- [Protara Therapeutics (NASDAQ:TARA) Downgraded to Strong Sell Rating by Wall Street Zen](https://longbridge.com/en/news/295992564.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**